



## **MEDIA ALERT: Webinar Scheduled About Contrast Management for Myopia Control**

Canadian eye care professionals are invited to attend an educational webinar examining the growing evidence base for contrast management as a method for slowing myopia progression in children. On April 15 at 6 p.m. PT (9 p.m. ET), SightGlass Vision will host *“Unlocking the Power of Contrast Management: Real-World Results with MiSight® Spectacle Lenses Powered by Diffusion Optics Technology™.”*

The session will feature Fabio Carta, Dip. Optom, FBCLA, Director of Professional Affairs at SightGlass Vision, and Dr. Kylvin Ho, Optometrist, FIAOMC, of C U Vision Optometrists in Vancouver, a leading myopia control optometrist.

Canadian eye care professionals interested in attending the webinar can [register here](#).

The webinar will explore how managing contrast works to help control myopia, bridging the underlying science with practical application in clinical care. Carta will introduce eye care professionals to DOT™ spectacle lenses—available in Canada as MiSight® Spectacle Lenses powered by Diffusion Optics Technology™—the first myopia management treatment specifically designed to reduce retinal contrast signaling through the incorporation of light scattering elements.<sup>[1]</sup> He will also review clinical research showing that the lenses can slow myopia progression by up to 75% after 12 months of wear across diverse patient populations.<sup>1,[2]\*</sup>

Dr. Ho will then share real-world clinical cases from his experience prescribing the lenses in practice, providing a peer-to-peer perspective into how the lenses are helping his patients. The session will conclude with a Q&A for attendees.

For more information on the April 15 webinar, [visit the registration page](#).

###

*\*Patient population aged 6–10 years (CYPRESS) and 6–13 years (CATHAY). Prescribed DOT lens wear time was 10 hours per day.*

### **About SightGlass Vision**

SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light-scattering elements designed to mimic more natural contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperVision, Inc. and Essilor International to accelerate commercialization opportunities and expand the myopia management category worldwide.

*MiSight® Spectacle Lenses powered by Diffusion Optics Technology™ are not available for sale in the U.S.*

*Diffusion Optics Technology and DOT are trademarks of SightGlass Vision, Inc. © 2026 SightGlass Vision, Inc. All Rights Reserved.*

---

<sup>[1]</sup> Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study. *Br J Ophthalmol.* 2023;107:1709-1715.

<sup>[2]</sup> Laughton et al. Control of myopia using contrast modulation spectacle lenses in a Chinese population: 12-month results. *Invest. Ophthalmol. Vis. Sci.* 2025;66(8):2815.